Difference between revisions of "Non-pegylated liposomal doxorubicin (Myocet)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *7/13/2000: Initial marketing authorization as Myocet. |
| + | *Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic [[breast cancer]] in adult women. | ||
==Also known as== | ==Also known as== | ||
| Line 24: | Line 25: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| − | [[Category:EMA approved | + | [[Category:EMA approved in 2000]] |
[[Category:Health Canada approved drugs]] | [[Category:Health Canada approved drugs]] | ||
Revision as of 13:35, 5 December 2021
General information
Class/mechanism: A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity.
Diseases for which it is used
History of changes in EMA indication
- 7/13/2000: Initial marketing authorization as Myocet.
- Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Also known as
- Generic names: liposome-encapsulated doxorubicin citrate, NPLD
- Brand name: Myocet